Recently, targeting multiple modes of PI3K and its compensatory pathways like KRAS and YAP/YEAD has been suggested to benefit KRAS-driven tumors [98], but further investigation is needed in gynecological cancers. This evidence concerns the gene YAP1 and female reproductive organ cancer.